长效重组蛋白药物的研究进展

被引：24

作者：

戚楠

马清钧

机构：

[1] 军事医学科学院生物工程所

来源：

中国生物工程杂志 | 2006年 / 02期

关键词：

长效重组蛋白药物; 半衰期; 分子量; 药物平衡; 免疫原性; 突变体; PEG化; 血清白蛋白;

D O I：

10.13523/j.cb.20060217

中图分类号：

R977.6 [蛋白质、结合糖、脂类];

学科分类号：

摘要：

重组蛋白药物经静脉和皮下注射后通常半衰期较短,目前延长蛋白药物半衰期的方法主要基于三种原理:1、增大蛋白药物分子量;2、利用血浆药物平衡;3、减少免疫原性。针对构建突变体、PEG化修饰和与血清白蛋白融合三种延长重组蛋白药物半衰期的方法,及其已上市的和正在研发中的长效重组蛋白药物的特征、半衰期和免疫原性问题进行了综述。

引用

页码：79 / 82

页数：4

共 22 条

[1]

PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization. Lee G K. Biotechnology and Bioengineering . 2005

[2]

Glycoengineering:the effect of glycosylation on the properties of therapeutic proteins. Sinclair A M,Elliott S. Journal of Pharmacological Sciences . 2005

[3]

Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique[J] . H. E. Scholtz,S. G. Pretorius,D. H. Wessels,R. H. A. Becker. &nbspDiabetologia . 2005 (10)

[4] Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice [J].

Melder, RJ ;

Osborn, BL ;

Riccobene, T ;

Kanakaraj, P ;

Wei, P ;

Chen, GX ;

Stolow, D ;

Halpern, WG ;

Migone, TS ;

Wang, Q ;

Grzegorzewski, KJ ;

Gallant, G .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (06) :535-547

[5]

Albugranin TM , a Recombinant Human Granulocyte Colony Stimulating Factor (G-CSF) Genetically Fused to Recombinant Human Albumin Induces Prolonged Myelopoietic Effects in Mice and Monkeys[J] . Wendy Halpern,Todd A. Riccobene,Heidi Agostini,Kevin Baker,David Stolow,Mi-Li Gu,Jonathan Hirsch,Angela Mahoney,Jeffrey Carrell,Ernest Boyd,Krzysztof J. Grzegorzewski. &nbspPharmaceutical Research . 2002 (11)

[6]

Pharmaceutical Strategies Utilizing Recombinant Human Serum Albumin[J] . Victor Tuan Giam Chuang,Ulrich Kragh-Hansen,Masaki Otagiri. &nbspPharmaceutical Research . 2002 (5)

[7]

Epitope mapping and competitive binding of HSA drug site II ligands by NMR diffusion measurements. Lucas L H,Price K E,Larive C K. Journal of the American Chemical Society . 2004

[8]

Insulin glargine:an updated review of its use in the management of diabetes mellitus. Dunn C J,Plosker G L,Keating G M,et al. Drugs . 2003

[9]

Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. Osborn B L,Olsen H S,Nardelli B,et al. Journal of Pharmacology and Experimental Therapeutics . 2002

[10]

Phase I evaluation of a40kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. Talpaz M. Clinical Cancer Research . 2005

← 1 2 3 →